Theratechnologies Inc. (NASDAQ:THTX) Sees Large Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 31,900 shares, an increase of 212.7% from the January 31st total of 10,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 123,000 shares, the short-interest ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Stock Up 1.9 %

THTX traded up $0.03 during mid-day trading on Friday, reaching $1.65. 71,740 shares of the company traded hands, compared to its average volume of 117,445. The stock has a market capitalization of $75.87 million, a P/E ratio of -16.50 and a beta of 1.26. The company’s fifty day moving average price is $1.74 and its 200-day moving average price is $1.45. Theratechnologies has a 52-week low of $1.08 and a 52-week high of $2.18.

Institutional Investors Weigh In On Theratechnologies

A number of hedge funds have recently added to or reduced their stakes in THTX. Hillsdale Investment Management Inc. purchased a new stake in Theratechnologies during the 4th quarter valued at $108,000. National Bank of Canada FI raised its stake in Theratechnologies by 29.4% during the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after buying an additional 42,435 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Theratechnologies during the 4th quarter valued at $40,000. BNP Paribas Financial Markets bought a new stake in shares of Theratechnologies during the 4th quarter valued at $36,000. Finally, Wealthspire Advisors LLC grew its position in shares of Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after acquiring an additional 20,000 shares during the period.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.